Dr. Ron Taylor, a 2-time World Series winner and former Blue Jays team physician, dies at 87
Dr. Ron Taylor, a World Series champion pitcher with both the St. Louis Cardinals and New York Mets, who later became the Toronto Blue Jays' team physician, died Monday. He was 87.
Taylor died in Toronto after a long illness, the Mets said in a statement. A native of Toronto and a member of the Canadian Sports Hall of Fame, Taylor was part of the 1964 Cardinals and 1969 Mets championship teams. The right-hander pitched for the Mets from 1967–71. In 1969, he led the Miracle Mets with 59 appearances and 13 saves to go with a 9–4 record and a 2.72 ERA.
For all the latest headlines, follow our Google News channel online or via the app.
'Ron was the only guy on our staff with postseason experience,' former Mets teammate Art Shamsky said. 'He had won a championship with the Cardinals in 1964 and brought a winning mentality. We don't win the title without Ron Taylor.'
Taylor pitched 2 1/3 scoreless innings in the 1969 World Series and saved a 2–1 victory in Game 2 against Baltimore when he retired Hall of Famer Brooks Robinson with two runners on in the bottom of the ninth. Against Atlanta in the 1969 National League Championship Series, Taylor saved Game 1 and earned the win in Game 2.
Taylor's big league career spanned 11 seasons, beginning with Cleveland in 1962 and ending with San Diego in 1972. He also pitched for Houston from 1965–66 and finished 45–43 with a 3.93 ERA and 74 saves in 491 games, including 17 starts. After baseball, he enrolled in medical school and spent about three decades as the Blue Jays' team physician.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
5 hours ago
- Al Arabiya
Dr. Ron Taylor, a 2-time World Series winner and former Blue Jays team physician, dies at 87
Dr. Ron Taylor, a World Series champion pitcher with both the St. Louis Cardinals and New York Mets, who later became the Toronto Blue Jays' team physician, died Monday. He was 87. Taylor died in Toronto after a long illness, the Mets said in a statement. A native of Toronto and a member of the Canadian Sports Hall of Fame, Taylor was part of the 1964 Cardinals and 1969 Mets championship teams. The right-hander pitched for the Mets from 1967–71. In 1969, he led the Miracle Mets with 59 appearances and 13 saves to go with a 9–4 record and a 2.72 ERA. For all the latest headlines, follow our Google News channel online or via the app. 'Ron was the only guy on our staff with postseason experience,' former Mets teammate Art Shamsky said. 'He had won a championship with the Cardinals in 1964 and brought a winning mentality. We don't win the title without Ron Taylor.' Taylor pitched 2 1/3 scoreless innings in the 1969 World Series and saved a 2–1 victory in Game 2 against Baltimore when he retired Hall of Famer Brooks Robinson with two runners on in the bottom of the ninth. Against Atlanta in the 1969 National League Championship Series, Taylor saved Game 1 and earned the win in Game 2. Taylor's big league career spanned 11 seasons, beginning with Cleveland in 1962 and ending with San Diego in 1972. He also pitched for Houston from 1965–66 and finished 45–43 with a 3.93 ERA and 74 saves in 491 games, including 17 starts. After baseball, he enrolled in medical school and spent about three decades as the Blue Jays' team physician.
Al Arabiya
6 hours ago
- Al Arabiya
No-Hit Loss Won't Erase the Lifetime Memories Made by Murray State During Its Improbable Run
The stands at Charles Schwab Field were emptying, and Murray State players wanted to savor their program's first College World Series appearance as long as they could. Never mind the Racers had just been no-hit by Arkansas's Gage Wood in a 3–0 loss that would send them home to southwestern Kentucky on Tuesday. Some of the players filled jars with infield dirt–a keepsake from their improbable journey to the city where every college baseball team wants to be in June. Some milled about with family and friends. 'One of my wife's favorite movies is 'A League of Their Own,' and they said 'there's no crying in baseball,'' an emotional coach Dan Skirka said to open his postgame news conference, with 9-year-old son Keegan on his knee. 'Well, throw that out the window. There's no way I'm making it through this right here.' For all the latest headlines, follow our Google News channel online or via the app. The Racers were the first Missouri Valley Conference team to make the CWS since 2003 and only the fourth No. 4 regional seed to get to Omaha since the NCAA Tournament went to its current format in 1999. They swept conference regular-season and tournament championships, beat No. 10 national seed Mississippi of the SEC twice on its home field and Georgia Tech of the ACC once en route to a regional title. Then the Racers went to Duke of the ACC for super regionals and lost the opener before winning two straight to punch their ticket to Omaha. Murray State overcame early jitters in its CWS opener against UCLA, falling behind 6–0 and losing 6–4. As for their game against Arkansas, the Racers just happened to run into a pitcher who threw one of the greatest games in college baseball history–a no-hitter with nineteen strikeouts, a record in a nine-inning CWS game and tied for most by a Division I pitcher this season. 'We never lost faith. Haven't all year. We're not about to start now,' third baseman Carson Garner said. 'About halfway through the game I think we realized that, 'Hey, this guy's, he's dealing, he's throwing a perfect game.'' Murray State finished 44–17 to set a program record for wins, ending the season with only its second shutout loss. 'The wins are phenomenal. We had a lot of them,' said Jonathan Hogart, who led the Racers with twenty-two homers. 'You just can't match the culture we have here. I'm going to miss Coach, I'm going to miss these two (Garner and Dustin Mercer). I'm going to miss every one of these guys. Strapping on the cleats to go to war with these guys was such a blessing this year, and I'll never take it for granted.' Skirka, who finished his seventh season as the Racers' coach, put together a roster made up of eight Division I transfers, fourteen from junior colleges, and fourteen high school recruits. Skirka said no one on his team was making money from endorsements or other name, image, and likeness opportunities. 'You say at the end of the year only one team's happy,' Skirka said. 'That ain't the case this year. There's definitely more than one because these guys, the run they went on, you're not going to be able to wipe the smile off their face for a really long time. That's what I told them. They're going to share this for ages, and people are going to ask them about it for ages, and that's really the cool thing.'
Al Arabiya
9 hours ago
- Al Arabiya
Second Patient Death Reported With Gene Therapy for Muscular Dystrophy
Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy Elevidys for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility, and early death in males. Elevidys is the first gene therapy approved in the US for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system-suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older regardless of whether they are still able to walk. Previously, it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts–based company fell more than 42 percent to close at about 21 in trading. Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership. 'Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,' said Leerink Partners analyst Joseph Schwartz in a Sunday research note. Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion.
